The Senescence-Inhibitory P53 Isoform Δ133P53Α Represses The Proinflammatory Chemokine Cxcl10 In Progeria Model Mice And Naturally Aged Mice

Aging Pathway
Therapeutic
The p53 isoform Δ133p53α reduces levels of the proinflammatory chemokine CXCL10 in both progeria model mice and naturally aged mice, suggesting a role in counteracting aging-associated inflammation.
Author

Gemini

Published

April 13, 2026

Our bodies naturally produce different versions of important proteins. One such variant, called Δ133p53α, is a natural form of the well-known p53 protein, which plays a crucial role in cell health. This particular variant has been found to help prevent cells from entering a state called “cellular senescence,” where they stop dividing and contribute to aging and inflammation.

In a recent study, researchers investigated the effects of Δ133p53α in mice, including those with a condition called progeria, which causes accelerated aging, and naturally aged mice. They discovered that Δ133p53α significantly reduces the levels of a signaling molecule known as CXCL10. CXCL10 is a “proinflammatory chemokine,” meaning it acts like a beacon, attracting immune cells and fueling inflammation in the body.

This finding is important because it suggests that CXCL10 is a key player in the inflammation associated with both accelerated and normal aging. By showing that Δ133p53α can repress CXCL10, this research highlights a potential new pathway for developing therapies that could target inflammation and potentially slow down aspects of the aging process.


Source: link to paper